Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio
Identifieur interne : 002990 ( Istex/Corpus ); précédent : 002989; suivant : 002991Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio
Auteurs : Marios Politis ; Wolfgang H. Oertel ; Kit Wu ; Niall P. Quinn ; Oliver Pogarell ; David J. Brooks ; Anders Bjorklund ; Olle Lindvall ; Paola PicciniSource :
- Movement Disorders [ 0885-3185 ] ; 2011-09.
English descriptors
Abstract
Graft‐induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF‐medication graft‐induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single‐photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5‐HT1A agonist suppressed graft‐induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft‐induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft‐induced dyskinesias. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23743
Links to Exploration step
ISTEX:18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
<author><name sortKey="Politis, Marios" sort="Politis, Marios" uniqKey="Politis M" first="Marios" last="Politis">Marios Politis</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation><mods:affiliation>Department of Neurology, Philipps‐University, Marburg, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Wu, Kit" sort="Wu, Kit" uniqKey="Wu K" first="Kit" last="Wu">Kit Wu</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
<affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
<affiliation><mods:affiliation>Department of Psychiatry, Ludwig‐Maximilian‐University of Munich, Munich, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bjorklund, Anders" sort="Bjorklund, Anders" uniqKey="Bjorklund A" first="Anders" last="Bjorklund">Anders Bjorklund</name>
<affiliation><mods:affiliation>Neurobiology Unit, Wallenberg Neuroscience Center, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lindvall, Olle" sort="Lindvall, Olle" uniqKey="Lindvall O" first="Olle" last="Lindvall">Olle Lindvall</name>
<affiliation><mods:affiliation>Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund, Sweden</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Lund Stem Cell Center, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Piccini, Paola" sort="Piccini, Paola" uniqKey="Piccini P" first="Paola" last="Piccini">Paola Piccini</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23743</idno>
<idno type="url">https://api.istex.fr/document/18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002990</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
<author><name sortKey="Politis, Marios" sort="Politis, Marios" uniqKey="Politis M" first="Marios" last="Politis">Marios Politis</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation><mods:affiliation>Department of Neurology, Philipps‐University, Marburg, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Wu, Kit" sort="Wu, Kit" uniqKey="Wu K" first="Kit" last="Wu">Kit Wu</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
<affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
<affiliation><mods:affiliation>Department of Psychiatry, Ludwig‐Maximilian‐University of Munich, Munich, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bjorklund, Anders" sort="Bjorklund, Anders" uniqKey="Bjorklund A" first="Anders" last="Bjorklund">Anders Bjorklund</name>
<affiliation><mods:affiliation>Neurobiology Unit, Wallenberg Neuroscience Center, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lindvall, Olle" sort="Lindvall, Olle" uniqKey="Lindvall O" first="Olle" last="Lindvall">Olle Lindvall</name>
<affiliation><mods:affiliation>Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund, Sweden</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Lund Stem Cell Center, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Piccini, Paola" sort="Piccini, Paola" uniqKey="Piccini P" first="Paola" last="Piccini">Paola Piccini</name>
<affiliation><mods:affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-09">2011-09</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1997">1997</biblScope>
<biblScope unit="page" to="2003">2003</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4</idno>
<idno type="DOI">10.1002/mds.23743</idno>
<idno type="ArticleID">MDS23743</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson</term>
<term>dyskinesias</term>
<term>serotonin transporter; dopamine transporter</term>
<term>transplantation</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Graft‐induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF‐medication graft‐induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single‐photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5‐HT1A agonist suppressed graft‐induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft‐induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft‐induced dyskinesias. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<author><json:item><name>Marios Politis MD, PhD</name>
<affiliations><json:string>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
<json:string>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Wolfgang H. Oertel MD, PhD</name>
<affiliations><json:string>Department of Neurology, Philipps‐University, Marburg, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>Kit Wu MRCP</name>
<affiliations><json:string>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
<json:string>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Niall P. Quinn MD</name>
<affiliations><json:string>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Oliver Pogarell MD</name>
<affiliations><json:string>Department of Psychiatry, Ludwig‐Maximilian‐University of Munich, Munich, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>David J. Brooks MD, DSc, FRCP, FMedSci</name>
<affiliations><json:string>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
<json:string>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Anders Bjorklund PhD</name>
<affiliations><json:string>Neurobiology Unit, Wallenberg Neuroscience Center, Lund, Sweden</json:string>
</affiliations>
</json:item>
<json:item><name>Olle Lindvall MD, PhD</name>
<affiliations><json:string>Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund, Sweden</json:string>
<json:string>Lund Stem Cell Center, Lund, Sweden</json:string>
</affiliations>
</json:item>
<json:item><name>Paola Piccini MD, PhD, FRCP</name>
<affiliations><json:string>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
<json:string>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>Parkinson</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>transplantation</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>dyskinesias</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>serotonin transporter; dopamine transporter</value>
</json:item>
</subject>
<language><json:string>eng</json:string>
</language>
<abstract>Graft‐induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF‐medication graft‐induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single‐photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5‐HT1A agonist suppressed graft‐induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft‐induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft‐induced dyskinesias. © 2011 Movement Disorder Society</abstract>
<qualityIndicators><score>4.869</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>612 x 810 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>1110</abstractCharCount>
<pdfWordCount>3201</pdfWordCount>
<pdfCharCount>19880</pdfCharCount>
<pdfPageCount>7</pdfPageCount>
<abstractWordCount>139</abstractWordCount>
</qualityIndicators>
<title>Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
<genre><json:string>Serial article</json:string>
</genre>
<host><volume>26</volume>
<pages><total>7</total>
<last>2003</last>
<first>1997</first>
</pages>
<issn><json:string>0885-3185</json:string>
</issn>
<issue>11</issue>
<subject><json:item><value>Research Article</value>
</json:item>
</subject>
<genre></genre>
<language><json:string>unknown</json:string>
</language>
<title>Movement Disorders</title>
<doi><json:string>10.1002/(ISSN)1531-8257</json:string>
</doi>
</host>
<publicationDate>2011</publicationDate>
<copyrightDate>2011</copyrightDate>
<doi><json:string>10.1002/mds.23743</json:string>
</doi>
<id>18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4</id>
<fulltext><json:item><original>true</original>
<mimetype>application/pdf</mimetype>
<extension>pdf</extension>
<uri>https://api.istex.fr/document/18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4/fulltext/pdf</uri>
</json:item>
<json:item><original>false</original>
<mimetype>application/zip</mimetype>
<extension>zip</extension>
<uri>https://api.istex.fr/document/18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability><p>Wiley Subscription Services, Inc., A Wiley Company</p>
</availability>
<date>2011</date>
</publicationStmt>
<notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note>
<note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
<author><persName><forename type="first">Marios</forename>
<surname>Politis</surname>
<roleName type="degree">MD, PhD</roleName>
</persName>
<note type="correspondence"><p>Correspondence: Cyclotron Building, Hammersmith Hospital, Imperial College London, London W12 0NN, UK</p>
</note>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Wolfgang H.</forename>
<surname>Oertel</surname>
<roleName type="degree">MD, PhD</roleName>
</persName>
<affiliation>Department of Neurology, Philipps‐University, Marburg, Germany</affiliation>
</author>
<author><persName><forename type="first">Kit</forename>
<surname>Wu</surname>
<roleName type="degree">MRCP</roleName>
</persName>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Niall P.</forename>
<surname>Quinn</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Oliver</forename>
<surname>Pogarell</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Department of Psychiatry, Ludwig‐Maximilian‐University of Munich, Munich, Germany</affiliation>
</author>
<author><persName><forename type="first">David J.</forename>
<surname>Brooks</surname>
<roleName type="degree">MD, DSc, FRCP, FMedSci</roleName>
</persName>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Anders</forename>
<surname>Bjorklund</surname>
<roleName type="degree">PhD</roleName>
</persName>
<affiliation>Neurobiology Unit, Wallenberg Neuroscience Center, Lund, Sweden</affiliation>
</author>
<author><persName><forename type="first">Olle</forename>
<surname>Lindvall</surname>
<roleName type="degree">MD, PhD</roleName>
</persName>
<affiliation>Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund, Sweden</affiliation>
<affiliation>Lund Stem Cell Center, Lund, Sweden</affiliation>
</author>
<author><persName><forename type="first">Paola</forename>
<surname>Piccini</surname>
<roleName type="degree">MD, PhD, FRCP</roleName>
</persName>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
</author>
</analytic>
<monogr><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="pISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<idno type="DOI">10.1002/(ISSN)1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-09"></date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1997">1997</biblScope>
<biblScope unit="page" to="2003">2003</biblScope>
</imprint>
</monogr>
<idno type="istex">18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4</idno>
<idno type="DOI">10.1002/mds.23743</idno>
<idno type="ArticleID">MDS23743</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2011</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Graft‐induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF‐medication graft‐induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single‐photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5‐HT1A agonist suppressed graft‐induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft‐induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft‐induced dyskinesias. © 2011 Movement Disorder Society</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head>
<item><term>Parkinson</term>
</item>
<item><term>transplantation</term>
</item>
<item><term>dyskinesias</term>
</item>
<item><term>serotonin transporter; dopamine transporter</term>
</item>
</list>
</keywords>
</textClass>
<textClass><keywords scheme="Journal Subject"><list><head>Article category</head>
<item><term>Research Article</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="2011-01-22">Received</change>
<change when="2011-03-15">Registration</change>
<change when="2011-09">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><original>false</original>
<mimetype>text/plain</mimetype>
<extension>txt</extension>
<uri>https://api.istex.fr/document/18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1531-8257</doi>
<issn type="print">0885-3185</issn>
<issn type="electronic">1531-8257</issn>
<idGroup><id type="product" value="MDS"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title>
<title type="short">Mov. Disord.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v26.11</doi>
<numberingGroup><numbering type="journalVolume" number="26">26</numbering>
<numbering type="journalIssue">11</numbering>
</numberingGroup>
<coverDate startDate="2011-09">September 2011</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23743</doi>
<idGroup><id type="unit" value="MDS23743"></id>
</idGroup>
<countGroup><count type="pageTotal" number="7"></count>
</countGroup>
<titleGroup><title type="articleCategory">Research Article</title>
<title type="tocHeading1">Research Articles</title>
</titleGroup>
<copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright>
<eventGroup><event type="manuscriptReceived" date="2011-01-22"></event>
<event type="manuscriptRevised" date="2011-03-02"></event>
<event type="manuscriptAccepted" date="2011-03-15"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.10 mode:FullText" date="2011-09-19"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2011-05-24"></event>
<event type="firstOnline" date="2011-05-24"></event>
<event type="publishedOnlineFinalForm" date="2011-09-19"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">1997</numbering>
<numbering type="pageLast">2003</numbering>
</numberingGroup>
<correspondenceTo>Cyclotron Building, Hammersmith Hospital, Imperial College London, London W12 0NN, UK</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23743.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="4"></count>
<count type="tableTotal" number="1"></count>
<count type="referenceTotal" number="20"></count>
<count type="wordTotal" number="4367"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio<link href="#fn1"></link>
<link href="#fn2"></link>
</title>
<title type="short" xml:lang="en">SERT/DAT in PD Patient with GIDS</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Marios</givenNames>
<familyName>Politis</familyName>
<degrees>MD, PhD</degrees>
</personName>
<contactDetails><email>marios.politis@imperial.ac.uk</email>
</contactDetails>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Wolfgang H.</givenNames>
<familyName>Oertel</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Kit</givenNames>
<familyName>Wu</familyName>
<degrees>MRCP</degrees>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Niall P.</givenNames>
<familyName>Quinn</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Oliver</givenNames>
<familyName>Pogarell</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>David J.</givenNames>
<familyName>Brooks</familyName>
<degrees>MD, DSc, FRCP, FMedSci</degrees>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Anders</givenNames>
<familyName>Bjorklund</familyName>
<degrees>PhD</degrees>
</personName>
</creator>
<creator xml:id="au8" creatorRole="author" affiliationRef="#af7 #af8"><personName><givenNames>Olle</givenNames>
<familyName>Lindvall</familyName>
<degrees>MD, PhD</degrees>
</personName>
</creator>
<creator xml:id="au9" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Paola</givenNames>
<familyName>Piccini</familyName>
<degrees>MD, PhD, FRCP</degrees>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Philipps‐University, Marburg, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="DE" type="organization"><unparsedAffiliation>Department of Psychiatry, Ludwig‐Maximilian‐University of Munich, Munich, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af6" countryCode="SE" type="organization"><unparsedAffiliation>Neurobiology Unit, Wallenberg Neuroscience Center, Lund, Sweden</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af7" countryCode="SE" type="organization"><unparsedAffiliation>Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund, Sweden</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Lund Stem Cell Center, Lund, Sweden</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson</keyword>
<keyword xml:id="kwd2">transplantation</keyword>
<keyword xml:id="kwd3">dyskinesias</keyword>
<keyword xml:id="kwd4">serotonin transporter; dopamine transporter</keyword>
</keywordGroup>
<supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p>
<supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23743:MDS_23743_sm_suppinfomovie1"></mediaResource>
<caption>Supporting Information</caption>
</supportingInfoItem>
<supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23743:MDS_23743_sm_suppinfomovie2"></mediaResource>
<caption>Supporting Information</caption>
</supportingInfoItem>
</supportingInformation>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>Graft‐induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF‐medication graft‐induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single‐photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5‐HT<sub>1A</sub>
agonist suppressed graft‐induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft‐induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft‐induced dyskinesias. © 2011 Movement Disorder Society</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup><note xml:id="fn1"><p>Relevant conflicts of interest/financial disclosures: Nothing to report.</p>
</note>
<note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>SERT/DAT in PD Patient with GIDS</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio</title>
</titleInfo>
<name type="personal"><namePart type="given">Marios</namePart>
<namePart type="family">Politis</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<description>Correspondence: Cyclotron Building, Hammersmith Hospital, Imperial College London, London W12 0NN, UK</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Wolfgang H.</namePart>
<namePart type="family">Oertel</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Department of Neurology, Philipps‐University, Marburg, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Kit</namePart>
<namePart type="family">Wu</namePart>
<namePart type="termsOfAddress">MRCP</namePart>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Niall P.</namePart>
<namePart type="family">Quinn</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Oliver</namePart>
<namePart type="family">Pogarell</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Department of Psychiatry, Ludwig‐Maximilian‐University of Munich, Munich, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">David J.</namePart>
<namePart type="family">Brooks</namePart>
<namePart type="termsOfAddress">MD, DSc, FRCP, FMedSci</namePart>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Anders</namePart>
<namePart type="family">Bjorklund</namePart>
<namePart type="termsOfAddress">PhD</namePart>
<affiliation>Neurobiology Unit, Wallenberg Neuroscience Center, Lund, Sweden</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Olle</namePart>
<namePart type="family">Lindvall</namePart>
<namePart type="termsOfAddress">MD, PhD</namePart>
<affiliation>Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund, Sweden</affiliation>
<affiliation>Lund Stem Cell Center, Lund, Sweden</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Paola</namePart>
<namePart type="family">Piccini</namePart>
<namePart type="termsOfAddress">MD, PhD, FRCP</namePart>
<affiliation>Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<affiliation>Clinical Sciences Center, Medical Research Council, Hammersmith Hospital, Imperial College London, London, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="originalCategForm">article</genre>
<originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place><placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2011-09</dateIssued>
<dateCaptured encoding="w3cdtf">2011-01-22</dateCaptured>
<dateValid encoding="w3cdtf">2011-03-15</dateValid>
<copyrightDate encoding="w3cdtf">2011</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="figures">4</extent>
<extent unit="tables">1</extent>
<extent unit="references">20</extent>
<extent unit="words">4367</extent>
</physicalDescription>
<abstract lang="en">Graft‐induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF‐medication graft‐induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single‐photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5‐HT1A agonist suppressed graft‐induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft‐induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft‐induced dyskinesias. © 2011 Movement Disorder Society</abstract>
<note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note>
<note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note>
<subject lang="en"><genre>Keywords</genre>
<topic>Parkinson</topic>
<topic>transplantation</topic>
<topic>dyskinesias</topic>
<topic>serotonin transporter; dopamine transporter</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Movement Disorders</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Mov. Disord.</title>
</titleInfo>
<note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information - Supporting Information - </note>
<subject><genre>article category</genre>
<topic>Research Article</topic>
</subject>
<identifier type="ISSN">0885-3185</identifier>
<identifier type="eISSN">1531-8257</identifier>
<identifier type="DOI">10.1002/(ISSN)1531-8257</identifier>
<identifier type="PublisherID">MDS</identifier>
<part><date>2011</date>
<detail type="volume"><caption>vol.</caption>
<number>26</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>11</number>
</detail>
<extent unit="pages"><start>1997</start>
<end>2003</end>
<total>7</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4</identifier>
<identifier type="DOI">10.1002/mds.23743</identifier>
<identifier type="ArticleID">MDS23743</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition>
<recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
<recordContentSource>WILEY</recordContentSource>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002990 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002990 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:18EE56D4C431BCFCA2CE9F0A0F6D9A9CE2E412F4 |texte= Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |